Anti-infective Agents Market Size & Growth Forecast 2026–2035, By Segments (Distribution Channel, Type, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Anti-infective Agents Market size was more than USD 136.2 Billion in 2025 and is set to grow at a 1.7% CAGR between 2026 and 2035, reaching USD 161.21 Billion by 2035. The industry revenue for 2026 is estimated at USD 138.16 billion.

• Base Year Value (2025): USD 136.2 Billion
• CAGR (2026-2035): 1.7%
• Forecast Year Value (2035): USD 161.21 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Anti-infective Agents Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds 40.39% share due to established treatment systems, broad prescription access, and consistent use across hospitals, outpatient care, and long-term care settings.
  • Asia Pacific grows at 1.94% CAGR, driven by expanding healthcare access, rising patient treatment uptake, and broader availability of essential anti-infective therapies.

• Segment Momentum:

  • Hospital Pharmacies held a 51.41% market share in 2025, driven by their central role in dispensing injectable therapies, supporting inpatient treatment, and managing physician-directed infection care.
  • Antifungals are the fastest-growing type segment as demand rises for targeted treatment of serious fungal infections, particularly among vulnerable patient groups requiring timely and effective therapy.

• Market Expansion Drivers:

  • Rising global infectious disease burden increasing demand for targeted antimicrobial therapies.
  • Government-funded R&D programs accelerating development of novel antiviral and antibacterial drugs.
  • Growth of antimicrobial resistance driving innovation in next-generation therapeutic solutions.

• Leading Market Participants:

  Major companies in the anti-infective agents market include Pfizer Inc. (United States), Bayer AG (Germany), AbbVie Inc. (United States), Gilead Sciences, Inc. (United States), Bristol-Myers Squibb Company (United States), Merck & Co., Inc. (United States), Johnson & Johnson (United States), AstraZeneca plc (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Sandoz Group AG (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 136.2 Billion
  • Projected Market Size: USD 161.21 Billion by 2035
  • Growth Forecasts: 1.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hospital Pharmacies (Distribution Channel) | Antivirals (Type) | Oral (Route of Administration)
  • Emerging Opportunity Segment: Retail Pharmacies (Distribution Channel) | Antifungals (Type) | Parenteral (Route of Administration)

Market Growth Drivers and Industry Trends

Rising global infectious disease burden increasing demand for targeted antimicrobial therapies

As infection incidence remains elevated across respiratory, bloodstream, gastrointestinal, and hospital-acquired conditions, prescribing behavior is shifting toward faster, more precise treatment selection, driving demand for the anti-infective agents market. Clinicians and health systems are placing greater emphasis on targeted antimicrobial therapies that can improve pathogen-specific response, reduce treatment failure, and limit unnecessary broad-spectrum use, especially where patient acuity and resistance risk are high. This dynamic strengthens market development by increasing utilization of differentiated anti-infective agents, supporting uptake of therapies aligned with diagnostic-led care pathways and infection management protocols.

Government-funded R&D programs accelerating development of novel antiviral and antibacterial drugs

Public-sector R&D support is reducing part of the scientific and financial risk that has historically constrained anti-infective innovation, particularly in areas where commercial returns can be uncertain. In the anti-infective agents market, government-backed grants, partnerships, and development incentives help move antiviral and antibacterial candidates through early research, clinical evaluation, and in some cases procurement-linked commercialization pathways. That intervention expands the active pipeline, attracts smaller biotechnology companies and larger pharmaceutical manufacturers into priority infection categories, and supports market expansion by increasing the flow of new therapies addressing unmet clinical needs.

Growth of antimicrobial resistance driving innovation in next-generation therapeutic solutions

The spread of antimicrobial resistance is undermining the effectiveness of established therapies, pushing developers and healthcare providers to prioritize treatments that can address resistant pathogens more reliably. In the anti-infective agents market, this is influencing capital allocation, pipeline strategy, and formulary interest toward next-generation antibiotics, combination regimens, narrow-spectrum agents, and other advanced therapeutic approaches designed to overcome resistance mechanisms. As older drugs lose clinical utility in key care settings, resistance pressure is contributing to market size growth by creating replacement demand and strengthening adoption of differentiated products with clearer value in high-risk infections.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global infectious disease burden increasing demand for targeted antimicrobial therapies	2.30%	High	North America, Asia Pacific	High	Near Term
Government-funded R&D programs accelerating development of novel antiviral and antibacterial drugs	2.00%	High	Europe, North America	High	Mid Term
Growth of antimicrobial resistance driving innovation in next-generation therapeutic solutions	1.70%	High	Asia Pacific, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional share of 40.39% in 2025 in the anti-infective agents market, supported by its established treatment infrastructure, broad access to prescription therapies, and consistent use of anti-infective drugs across hospitals, outpatient settings, and long-term care. Demand in the region is reinforced by the high volume of diagnosed infectious conditions and the routine integration of branded and generic therapies into clinical practice. Market activity is also supported by strong pharmaceutical distribution networks and the presence of major manufacturers, which helps maintain product availability across therapeutic categories and supports steady prescribing patterns.

Asia Pacific is projected to expand at a 1.94% CAGR over the forecast period, with growth in the anti-infective agents market being propelled by rising healthcare access, expanding patient pools, and increasing treatment uptake across developing healthcare systems. Growth is accelerating as more patients enter formal care channels and as healthcare providers broaden the use of anti-infective therapies in both urban and emerging secondary markets. Practical adoption is being supported by ongoing improvements in healthcare delivery, wider medicine availability, and growing utilization of essential infectious disease treatments across a larger and more diverse population base.

Key Country Insights

United States

Antimicrobial Innovation Pipeline

The U.S. anti-infective agents market prioritizes the development of novel therapies addressing antimicrobial resistance and complex infectious diseases. Healthcare providers increasingly emphasize targeted treatments, stewardship programs, and rapid diagnostics to optimize clinical outcomes and responsible antimicrobial use.

Japan

Precision Infection Management

Japan focuses on precision infection management by combining advanced diagnostics with carefully selected anti-infective therapies. The Japanese market emphasizes optimized treatment pathways, hospital infection control, and products that support appropriate antimicrobial utilization.

South Korea

Rapid Treatment Adoption

South Korea advances the anti-infective agents market through rapid adoption of innovative therapies within technologically advanced healthcare systems. Clinical priorities include effective management of resistant infections, improved diagnostic integration, and efficient treatment protocols.

Germany

Hospital Stewardship Integration

Germany strengthens the anti-infective agents market through structured antimicrobial stewardship programs across hospitals and specialized care settings. German healthcare institutions increasingly adopt evidence-based prescribing practices while supporting demand for effective therapies against resistant pathogens.

France

Public Health Preparedness

France supports the anti-infective agents market through coordinated public health initiatives focused on infectious disease management and antimicrobial stewardship. Healthcare providers increasingly prioritize therapies that balance treatment effectiveness with responsible prescribing practices.

Italy

Clinical Care Optimization

Italy emphasizes optimized anti-infective therapy selection across hospitals to improve patient outcomes and address evolving resistance patterns. Italian healthcare providers increasingly integrate stewardship initiatives with diagnostic capabilities to support appropriate antimicrobial use.

Segment Leadership and Growth Trends

  Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)

Hospital Pharmacies held a 51.41% share of the anti-infective agents market in 2025, making them the leading distribution channel as treatment for acute and clinically supervised infections remains closely tied to hospital-based care. This leadership is maintained through the concentration of injectable anti-infective therapies, inpatient treatment protocols, and physician-directed dispensing within hospital settings. Hospital pharmacies also remain central where infection severity, antimicrobial stewardship, and immediate access to specialized therapies shape purchasing and administration patterns in the anti-infective agents market.

Retail Pharmacies are the fastest-growing distribution channel in the anti-infective agents market as a greater share of infection treatment is managed outside hospital settings. Their momentum is being reinforced through stronger demand for convenient access to prescribed oral therapies, especially for common community-managed conditions that do not require inpatient supervision. Compared with hospital channels, retail pharmacies are benefiting from broader consumer reach and easier refill access, which makes them well positioned as treatment pathways continue shifting toward outpatient care.

Type Segment Analysis: Antivirals (Largest Segment) vs Antifungals (Fastest-Growing Segment)

Antivirals accounted for a 53.45% share of the anti-infective agents market in 2025, positioning them as the largest type segment. Their leadership is reinforced through sustained clinical demand for managing widespread viral infections that often require structured, long-duration therapeutic use. In the anti-infective agents market, antivirals maintain this leading share because they are embedded in established treatment pathways and serve a broad patient base across both acute and chronic care settings.

Antifungals represent the fastest-growing type segment in the anti-infective agents market, encouraged by rising treatment needs in patient groups that are more vulnerable to fungal infections and require targeted therapy. Growth is being reinforced by the practical need for effective management of infections that can become serious when diagnosis or treatment is delayed. Relative to other anti-infective categories, antifungals are gaining momentum because they address a more expanding area of unmet clinical demand where treatment intensity and urgency are increasing.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Others	Hospital Pharmacies	Retail Pharmacies
Type	Antibacterials, Antivirals, Antifungals	Antivirals	Antifungals
Route of Administration	Oral, Parenteral, Topical, Others	Oral	Parenteral

Competitive Landscape and Market Positioning

Top players in the anti-infective agents market:

1. Pfizer Inc. (United States)

2. Bayer AG (Germany)

3. AbbVie Inc. (United States)

4. Gilead Sciences Inc. (United States)

5. Bristol-Myers Squibb Company (United States)

6. Merck & Co. Inc. (United States)

7. Johnson & Johnson (United States)

8. AstraZeneca plc (United Kingdom)

9. Boehringer Ingelheim International GmbH (Germany)

10. Sandoz Group AG (Switzerland)

The anti-infective agents market is evolving with continuous development of next-generation therapies designed to combat resistant pathogens and emerging infections. Strong research focus is enabling improved efficacy and broader therapeutic coverage. The anti-infective agents market is increasingly driven by innovation in infectious disease treatment strategies.

Industry Development/News

Company Name	Date	Key Development
Shionogi & Co.	Aug-24	Shionogi submitted a New Drug Application (NDA) for cefiderocol, a novel siderophore cephalosporin, to China's Center for Drug Evaluation. Cefiderocol, which targets multidrug-resistant Gram-negative bacteria, has demonstrated superior clinical efficacy in Phase III trials and is currently supporting the company’s broader strategic objective to expand global access to advanced antimicrobial treatments.
Sandoz	Mar-24	Sandoz inaugurated a new antibiotic production facility in Kundl, Austria, following a EUR 50 million investment. This expansion increases finished dosage form capacity by 20% to 240 million packages annually, significantly scaling the production of penicillin and pediatric formulations to address global supply shortages and bolster European manufacturing resilience.
Basilea Pharmaceutica	Jan-24	Basilea Pharmaceutica acquired a preclinical antibiotic program from Spexis AG, focused on novel LptA-inhibitors that disrupt Gram-negative bacterial lipopolysaccharide transport. This acquisition strengthens the company’s R&D pipeline against high-priority multidrug-resistant pathogens, strategically expanding its anti-infective portfolio to address unmet medical needs in hospital-based infection management.